Journals / İstanbul Medical Journal / 2015 / Cilt: 16 - Sayı: 4

Tamoksifen Kullanan Meme Kanserli Hastaların Smear Sonuçları

Pap Smear Results of Women with Breast Cancer Using Tamoxifen Therapy

Pages
149–151
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, pelvic examination and pap smear test are recommended for breast cancer patients annually.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pap Smear Results of Women with Breast Cancer Using Tamoxifen TherapyTamoksifen Kullanan Meme Kanserli Hastaların Smear SonuçlarıObjective: Our aim was to investigate the effect of tamoxifen on cervical smear of patients with breast cancer at our clinic.
📊
Key Findings & Data:Methods: The data of patients with breast cancer who had received tamoxifen were analyzed between 2006 and 2014, retrospectively.
💡
Conclusion & Impact:Therefore, pelvic examination and pap smear test are recommended for breast cancer patients annually.
🔬Design:Research Article
📍Scope:2006 Verileri
⚙️Variables:Domain Parameters

Abstract

Pap Smear Results of Women with Breast Cancer Using Tamoxifen TherapyTamoksifen Kullanan Meme Kanserli Hastaların Smear SonuçlarıObjective: Our aim was to investigate the effect of tamoxifen on cervical smear of patients with breast cancer at our clinic. Methods: The data of patients with breast cancer who had received tamoxifen were analyzed between 2006 and 2014, retrospectively. Pap smear results, age, gravidity, parity, smoking status, age of first birth, and detailed gynecologic and obstetric history of patients were noted. Patients who had not received at least one-year tamoxifen therapy and patients without cervicovaginal smear controls or those who left or had received interrupted tamoxifen treatment were exclud-ed. The pap smear results of the tamoxifen and control groups were analyzed.Results: A total of 246 patients (123 in the tamoxifen group and 123 in the control group) were included in this study. None of the patients had cervical squamous intraepithelial lesions and atypical glandular lesions. Atypical squamous cells were significantly higher in the tamoxifen group than in the control group (p=0.03).Conclusion: The use of tamoxifen may be associated with benign squamous atypia in cervical smears. Therefore, pelvic examination and pap smear test are recommended for breast cancer patients annually.

Özet

Amaç: Amacımız kliniğimizdeki tamoksifen kullanan meme kanserli hastalarda tamoksifenin serviko vajinal yayma üzerindeki etkisini araştırmaktır.Yöntemler: 2006-2014 arasında kliniğimizde tamoksifen kullanan meme kanserli hastaların verileri retrospektif olarak analiz edildi. Hastaların pap-smear sonuçları, yaş, gravida, parite, sigara içme durumu, ilk doğum yaşı, detaylı jinekolojik ve obstetrik öyküleri kaydedildi. Yayma kontrolleri olmayan, en az bir yıl tamoksifen tedavisi almayan ve tamoksifen tedavisini yarıda kesen ya da tedaviyi bırakan hastalar çalışma dışı bırakıldı. Grupların (tamoksifen ve kontrol grubu) yayma sonuçları analiz edildi. Bulgular: 246 hasta çalışmaya alındı (123 tamoksifen, 123 kontrol). Hastaların hiçbirinde servical skuamöz intraepitelyal lezyonlar ve atipik glandüler lezyon yoktu. Atipik skuamöz hücreler kontrol grubuna göre tamoksifen grubunda anlamlı olarak yüksek bulundu (p=0,03). Sonuç: Tamoxifen tedavisi servikal yaymalar incelendiğinde benign skuamöz atipi ile ilişkili olabilir. Bu nedenle, meme kanserli hastaların yıllık pelvik muayene ve pap-smear testi yaptırmaları önerilmektedir.

🔖

Cite This Article

MADENDAĞ, Y., GÖKSU, S. S., ÜNAL, D., AKSOY, H., UYSAL, G., ÇAĞLI, F., AÇMAZ, G., AKKAYA, H. (2022). Tamoksifen Kullanan Meme Kanserli Hastaların Smear Sonuçları. İstanbul Medical Journal, Cilt: 16 - Sayı: 4, 149–151. https://ajindex.com/articles/652063

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Maclean R, Jeffreys M, Ives A, Jones T, Verne J, Ben-Shlomo Y. Primary care characteristics and stage of cancer at diagnosis using data from the national cancer registration service, quality outcomes framework and general practice information. BMC Cancer 2015; 15: 500. [CrossRef] Ozmen V. Breast Cancer in Turkey. Turkiye Klinikleri J Gen Surg-Special Topics 2013; 6: 1-6. Jordan VC. An overview of considerations for the testing of tamoxifen as a preventive for breast cancer. Ann N Y Acad Sci 1995; 768: 141-7. [CrossRef] Curtis RE, Boice JD Jr, Shriner DA, Hankey BF, Fraumeni JF Jr. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Can- cer Inst 1996; 88: 832-4. [CrossRef] Jordan VC, Murphy CS. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 1990; 11: 578-610. [CrossRef] Karimi Zarchi M, Behtash N, Sekhavat L, Dehghan A. Effects of tamoxifen on the cervix and uterus in women with breast cancer: experience with Iranian patients and a literature review. Asian Pac J Cancer Prev 2009; 10: 595-8.
  2. Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant set- ting. J Clin Oncol 2006; 24: 5091-7. [CrossRef] Gill BL, Simpson JF, Somlo G, McGonigle KF, Wilczynski SP. Effects of Tamoxifen on the Cytology of the Uterine Cervix in Breast Cancer Pa- tients. Diagn Cytopathol 1998; 19: 417-22. [CrossRef] 9. Abadi MA, Barakat RR, Saigo PE. Effects of tamoxifen on cervicovaginal smears from patients with breast cancer. Acta Cytol 2000; 44: 141-6. [CrossRef] Fornander T, Rutqvist LE, Wilking N. Effects of tamoxifen on the fe- male genital tract. Ann N Y Acad Sci 1991; 622: 469-76. [CrossRef] Reeve BB, Mitchell SA, Dueck AC, Basch E, Cella D, Reilly CM, et al. Rec- ommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst 2014; 106: dju129. [CrossRef] Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988; 48: 812-5.
  3. Wolf DM, Jordan VC. Gynecologic complications associated with long- term adjuvant tamoxifen therapy for breast cancer. Gynecol Oncol 1992; 45: 118-8. [CrossRef] Hwang JY, Lin BY, Tang FM, Yu WC. Tamoxifen stimulates human pap- illomavirus type 16 gene expression and cell proliferation in a cervical cancer cell line. C